ALS Tissue Donation Program Impacts Research

In a collaborative study between the National Institute of Health, the University of Maryland and the University of Michigan, researchers used a 7 tesla (high intensity) MRI to image the donated brains from donors with ALS and compared the findings to those obtained from donors without ALS. The spinal cord, brain and muscle samples used in the study were recovered by the University of Maryland Brain and Tissue Bank, which is supported by a grant from the Blazeman Foundation. Dr. Kwan (co-author) provides a summary of the study. For a more in-depth analysis, read the journal article from NeuroImage: Clinical 15 (2017) 200-208.

ALS Research update from Brandeis

Dr. Rodal’s lab continues to investigate  how TDP-43 leads to growth signaling defects in the fruit fly model as well as  continuing to pursue the role of calcium channels in their mammalian models of ALS. Their progress report summarizes the past four years of research supported by the BMF and gives a look into next steps (how relevant are these pathways for progression of cellular pathology in human patients?). For a more detailed version of their work, please see the unabridged version.

BMF for ALS “Postdoctural Fellow” will examine a Protein’s Effect in Human Cells

The 10th Annual Blazeman Cycle for ALS

was held at Soul Cycle, Bronxville, NY  on Sunday, March 19th. A special thank you to Phil Gormley, who has organized this event since the beginning! Thank you for all you have done. Thank you for all who’ve participated from year one to now year 10, (unbelievable)… You are the constant warriors in the WarOnALS®. Only by making a continuous and concerted effort through “research” on all levels, will this “hideous disease-ALS” be destroyed.

Wake Forest Hsp70 research update

The Mulligan Lab is currently completing treatments of the SOD1G93A mouse model of ALS with four different doses of the Hsp70 protein and hopes to have the dose response study complete by the end of March/mid-April. With positive results (hopefully), our ALS scientists and clinicians will begin to design initial clinical trials in patients.